Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

09/08/2023

Caldwell, R. D. et al.; J. Med. Chem., 2019, 62(17), 7643-7655

Link to article